Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | ALPI | P09923 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724278 | 0.92 | MEN1 (0.38) | HTR2CRAB9AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5724205 | 0.92 | MEN1 (0.40) | HTR2CRAB9AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5724198 | 0.91 | MEN1 (0.42) | HTR2CRAB9AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5724107 | 0.90 | SMN1; SMN2 (0.39) | RAB9AALDH1A1L3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL5724414 | 0.90 | SCD (0.36) | HTR2CRAB9AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5724521 | 0.87 | RIPK1 (0.37) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5724728 | 0.85 | PTGER1 (0.41) | ALDH1A1L3MBTL1 | |
| SCHEMBL5724070 | 0.83 | SCD (0.48) | RAB9AL3MBTL1NPC1SMN1; SMN2 | |
| SCHEMBL5724344 | 0.82 | HTR2C (0.37) | HTR2CRAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL5723511 | 0.82 | OGA (0.38) | RAB9AL3MBTL1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340757-B1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO CO (JP) | 2006-10-11 | — | — | EP | disclosed |
| US-7001897-B2 | 1-methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-02-21 | — | — | US | disclosed |
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1340757-A1 | 1-METHYLCARBAPENEM DERIVATIVES | Sankyo Company, Limited (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014962-A1 | 1-Methylcarbapenem derivatives | CD14, CPT1A, ACMSD | HTR2C 4623/4885RAB9A 3028/4885ALDH1A1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.